About the Company
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VSTM News
Verastem: Q4 Earnings Snapshot
NEEDHAM, Mass. — NEEDHAM, Mass. — Verastem Inc. (VSTM) on Thursday reported a loss of $27.4 million in its fourth quarter. The Needham, Massachusetts-based company said it had a loss of $1.02 ...
Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Verastem (VSTM) BTIG analyst Justin Zelin reiterated a Buy ... Rani Therapeutics Holdings, and Apogee Therapeutics, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus ...
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
NDAQ:VSTM) Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates ...
Verastem, Inc. (VSTM) stock price, news, quote & history – Yahoo Finance
BOSTON, March 11, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced multiple oral and poster ...
Verastem: Q4 Earnings Snapshot
NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Thursday reported a loss of $27.4 million in its fourth quarter. The Needham, Massachusetts-based company said it had a loss of ...
Verastem, Inc. (VSTM) stock price, news, quote & history – Yahoo Finance
This strategic move has expanded Viking Global's holding to a total of 2,531,829 shares in Verastem Inc, reflecting the firm's confidence in the company's future prospects.
Loading the latest forecasts...